Payment overview · 2025
General Payments
$263.08
12 reported records · 10 companies
Healthcare provider profile · identity verified
David A. Ramos, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1003091976
Verified facts
What the public records show
CMS Open Payments records show David A. Ramos, MD received $263.08 in general payments during 2025 across 12 reported records.
Abbott Laboratories accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.28 | 17.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.60 | 16.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.36 | 13.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.88 | 9.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $22.31 | 8.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.07 | 8.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.11 | 7.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.86 | 7.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.07 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.54 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.08 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.28 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 618 | 180 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 191 |
| Losartan Potassium | Losartan Potassium | 370 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 112 |
| Metformin Hcl | Metformin Hcl | 208 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 77 |
| Alprazolam | Alprazolam | 184 | 34 |
| Lorazepam | Lorazepam | 161 | 36 |
| Lisinopril | Lisinopril | 155 | 55 |
| Pregabalin | Pregabalin | 153 | 48 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 153 | 61 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 152 | 57 |
| Gabapentin | Gabapentin | 150 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 22 |
| Montelukast Sodium | Montelukast Sodium | 138 | 51 |
| Clonazepam | Clonazepam | 130 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 23 |
| Omeprazole | Omeprazole | 119 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Nifedipine Er | Nifedipine | 114 | 44 |
| Ozempic | Semaglutide | 111 | 29 |
| Metformin Hcl Er | Metformin Hcl | 94 | 32 |
| Eszopiclone | Eszopiclone | 93 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 33 |
| Glipizide | Glipizide | 89 | 33 |
| Furosemide | Furosemide | 85 | 40 |
| Carvedilol | Carvedilol | 82 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 27 |
| Trazodone Hcl | Trazodone Hcl | 69 | 25 |
| Alendronate Sodium | Alendronate Sodium | 66 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 23 |
| Jardiance | Empagliflozin | 62 | 27 |
| Valsartan | Valsartan | 62 | 21 |
| Ibuprofen | Ibuprofen | 59 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 22 |
| Simvastatin | Simvastatin | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 50 | 20 |
| Baclofen | Baclofen | 46 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 15 |
| Potassium Chloride | Potassium Chloride | 43 | 14 |
| Sertraline Hcl | Sertraline Hcl | 43 | 15 |
| Azithromycin | Azithromycin | 40 | 35 |
| Finasteride | Finasteride | 40 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 13 |
| Ezetimibe | Ezetimibe | 36 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Allopurinol | Allopurinol | 33 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 17 |
| Linzess | Linaclotide | 33 | suppressed |
| Meloxicam | Meloxicam | 31 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | 11 |
| Famotidine | Famotidine | 28 | 14 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 12 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 15 |
| Eliquis | Apixaban | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 11 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.08 · 12 records | Abbott Laboratories | AREXVY, Auvelity, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Kerendia, LOREEV XR, NP Thyroid 60, REPATHA, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error